Literature DB >> 29655451

Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Michael H Rivner1, Mamatha Pasnoor2, Mazen M Dimachkie3, Richard J Barohn4, Lin Mei5.   

Abstract

Around 20% of patients with myasthenia gravis are acetylcholine receptor antibody negative; muscle-specific tyrosine kinase antibodies (MuSK) were identified as the cause of myasthenia gravis in 30% to 40% of these cases. Anti MuSK myasthenia gravis is associated with specific clinical phenotypes. One is a bulbar form with fewer ocular symptoms. Others show an isolated head drop or symptoms indistinguishable from acetylcholine receptor-positive myasthenia gravis. These patients usually respond well to immunosuppressive therapy, but not as well to cholinesterase inhibitors. Other antibodies associated with myasthenia gravis, including low-density lipoprotein receptor-related protein 4, are discussed.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Agrin; Cortactin; LRP4; MuSK; Myasthenia gravis; Rapsyn

Mesh:

Substances:

Year:  2018        PMID: 29655451      PMCID: PMC6051709          DOI: 10.1016/j.ncl.2018.01.004

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  162 in total

1.  A transient neonatal myasthenic syndrome with anti-musk antibodies.

Authors:  E H Niks; A Verrips; B A Semmekrot; M J J Prick; A Vincent; M J D van Tol; C M Jol-van der Zijde; J J G M Verschuuren
Journal:  Neurology       Date:  2008-04-01       Impact factor: 9.910

2.  Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice.

Authors:  Anna Rostedt Punga; Shuo Lin; Filippo Oliveri; Sarina Meinen; Markus A Rüegg
Journal:  Exp Neurol       Date:  2011-04-30       Impact factor: 5.330

3.  Identification of the mouse muscle 43,000-dalton acetylcholine receptor-associated protein (RAPsyn) by cDNA cloning.

Authors:  D E Frail; L L McLaughlin; J Mudd; J P Merlie
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

4.  Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies.

Authors:  Maria E Farrugia; Robin P Kennett; David Hilton-Jones; John Newsom-Davis; Angela Vincent
Journal:  Clin Neurophysiol       Date:  2006-12-08       Impact factor: 3.708

5.  Crosslinking of proteins in acetylcholine receptor-rich membranes: association between the beta-subunit and the 43 kd subsynaptic protein.

Authors:  S J Burden; R L DePalma; G S Gottesman
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

6.  Rapsyn mutations in myasthenic syndrome due to impaired receptor clustering.

Authors:  Ricardo A Maselli; Vanessa Dunne; Samuel Ignacio Pascual-Pascual; Constance Bowe; Mark Agius; Rochelle Frank; Robert L Wollmann
Journal:  Muscle Nerve       Date:  2003-09       Impact factor: 3.217

7.  Electrophysiological profile of the patients with MuSK positive myasthenia gravis.

Authors:  Ana Nikolic; Ivana Basta; Vidosava Rakocevic Stojanovic; Zorica Stevic; Dragana Lavrnic
Journal:  Neurol Res       Date:  2014-05-14       Impact factor: 2.448

8.  Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice.

Authors:  M Gautam; P G Noakes; J Mudd; M Nichol; G C Chu; J R Sanes; J P Merlie
Journal:  Nature       Date:  1995-09-21       Impact factor: 49.962

9.  Juvenile seropositive myasthenia gravis with anti-MuSK antibody after thymectomy.

Authors:  Anna Kostera-Pruszczyk; Hubert Kwiecinski
Journal:  J Neurol       Date:  2009-06-23       Impact factor: 4.849

10.  Treatment of MuSK-Associated Myasthenia Gravis.

Authors:  Khalid El-Salem; Ahmed Yassin; Kefah Al-Hayk; Salma Yahya; Duha Al-Shorafat; Said S Dahbour
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.972

View more
  8 in total

Review 1.  The mitochondrial biogenesis signaling pathway is a potential therapeutic target for myasthenia gravis via energy metabolism (Review).

Authors:  Lingling Ke; Qing Li; Jingwei Song; Wei Jiao; Aidong Ji; Tongkai Chen; Huafeng Pan; Yafang Song
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

Review 2.  Giant cell myositis associated with concurrent myasthenia gravis: a case-based review of the literature.

Authors:  Frank A Scangarello; Luisa Angel-Buitrago; Melanie Lang-Orsini; Alexander Geevarghese; Knarik Arkun; Oscar Soto; Mithila Vullaganti; Robert Kalish
Journal:  Clin Rheumatol       Date:  2021-02-25       Impact factor: 2.980

3.  Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.

Authors:  Sorabh Datta; Shivangi Singh; Raghav Govindarajan
Journal:  J Neuromuscul Dis       Date:  2020

Review 4.  Controversies in Ocular Myasthenia Gravis.

Authors:  Amelia Evoli; Raffaele Iorio
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

Review 5.  The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: a Narrative Review.

Authors:  Saiju Jacob; Gordon Mazibrada; Sarosh R Irani; Anu Jacob; Anna Yudina
Journal:  J Neuroimmune Pharmacol       Date:  2021-10-02       Impact factor: 4.147

6.  Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes.

Authors:  Qi Huang; Feng Li; Song Zhao
Journal:  BMC Neurol       Date:  2022-03-04       Impact factor: 2.474

7.  Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.

Authors:  Masaharu Takamori
Journal:  Front Mol Neurosci       Date:  2020-05-28       Impact factor: 5.639

Review 8.  Possible implications of dysregulated nicotinic acetylcholine receptor diffusion and nanocluster formation in myasthenia gravis.

Authors:  Francisco J Barrantes
Journal:  Neural Regen Res       Date:  2021-02       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.